Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the United States Adopted Names (USAN) Council has assigned the unique name "Buntanetap" for the Company's lead drug candidate...